Left Ventricular Dysfunction - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 57 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Left Ventricular Dysfunction - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Left Ventricular Dysfunction - Pipeline Review, H1 2015', provides an overview of the Left Ventricular Dysfunction's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Left Ventricular Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Left Ventricular Dysfunction and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Left Ventricular Dysfunction
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Left Ventricular Dysfunction and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Left Ventricular Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Left Ventricular Dysfunction pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Left Ventricular Dysfunction
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Left Ventricular Dysfunction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Left Ventricular Dysfunction Overview 6
Therapeutics Development 7
Pipeline Products for Left Ventricular Dysfunction - Overview 7
Pipeline Products for Left Ventricular Dysfunction - Comparative Analysis 8
Left Ventricular Dysfunction - Therapeutics under Development by Companies 9
Left Ventricular Dysfunction - Therapeutics under Investigation by Universities/Institutes 10
Left Ventricular Dysfunction - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Left Ventricular Dysfunction - Products under Development by Companies 14
Left Ventricular Dysfunction - Products under Investigation by Universities/Institutes 15
Left Ventricular Dysfunction - Companies Involved in Therapeutics Development 16
Acorda Therapeutics, Inc. 16
Amgen Inc. 17
Innopharmax Inc. 18
RedHill Biopharma Ltd. 19
Left Ventricular Dysfunction - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
CAP-1001 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
CAP-1002 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
carvedilol CR - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
carvedilol CR - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
cimaglermin alfa - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
CTX-101 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
omecamtiv mecarbil - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecule to Target O2 Radical for Left Ventricular Dysfunction and Diabetic Complications - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Left Ventricular Dysfunction - Recent Pipeline Updates 41
Left Ventricular Dysfunction - Dormant Projects 50
Left Ventricular Dysfunction - Discontinued Products 51
Left Ventricular Dysfunction - Product Development Milestones 52
Featured News & Press Releases 52
Aug 27, 2013: Amgen to Highlight New Data at Upcoming ESC Congress 2013 52
Jun 18, 2013: Cytokinetics Announces Presentation Of Results From Phase IIb Clinical Trial Of Omecamtiv Mecarbil At ESC Congress 2013 53
Feb 19, 2013: RedHill Biopharma Announces Notice Of Allowance From US Patent And Trademark Office For Cardio Drug RHB-101 54
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 56
Disclaimer 57

List of Tables
Number of Products under Development for Left Ventricular Dysfunction, H1 2015 7
Number of Products under Development for Left Ventricular Dysfunction - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Left Ventricular Dysfunction - Pipeline by Acorda Therapeutics, Inc., H1 2015 16
Left Ventricular Dysfunction - Pipeline by Amgen Inc., H1 2015 17
Left Ventricular Dysfunction - Pipeline by Innopharmax Inc., H1 2015 18
Left Ventricular Dysfunction - Pipeline by RedHill Biopharma Ltd., H1 2015 19
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Stage and Target, H1 2015 22
Number of Products by Stage and Mechanism of Action, H1 2015 24
Number of Products by Stage and Route of Administration, H1 2015 26
Number of Products by Stage and Molecule Type, H1 2015 28
Left Ventricular Dysfunction Therapeutics - Recent Pipeline Updates, H1 2015 41
Left Ventricular Dysfunction - Dormant Projects, H1 2015 50
Left Ventricular Dysfunction - Discontinued Products, H1 2015 51